Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

PRIMARY OBJECTIVES: I. To characterize the clinical anti-tumor activity of CDX-011 (glembatumumab vedotin) as a single-agent in the treatment of patients with metastatic uveal melanoma. SECONDARY OBJECTIVES: I. Description of the clinical safety and benefit of CDX-011 (glembatumumab vedotin) and pharmacodynamics changes in glycoprotein NMB (glycoprotein \[transmembrane\] NMB) (GPNMB) expression. TERTIARY OBJECTIVES: I. Characterization of the anti-tumor immunophenotype of patients receiving treatment. II. Post hoc, correlation of rash with clinical benefit, or lack of rash with lack of benefit, will also be explored. OUTLINE: Patients receive glembatumumab vedotin intravenously (IV) over 90 minutes every 3 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days.